Navigation Links
T-cell therapy eradicates an aggressive leukemia in 2 children
Date:3/25/2013

Two children with an aggressive form of childhood leukemia had a complete remission of their diseaseshowing no evidence of cancer cells in their bodiesafter treatment with a novel cell therapy that reprogrammed their immune cells to rapidly multiply and destroy leukemia cells. A research team from The Children's Hospital of Philadelphia and the University of Pennsylvania published the case report of two pediatric patients Online First today in The New England Journal of Medicine. It will appear in the April 18 print issue.

One of the patients, 7-year-old Emily Whitehead, was featured in news stories in December 2012 after the experimental therapy led to her dramatic recovery after she relapsed following conventional treatment. Emily remains healthy and cancer-free, 11 months after receiving bioengineered T cells that zeroed in on a target found in this type of leukemia, called acute lymphoblastic leukemia (ALL).

The other patient, a 10-year-old girl, who also had a complete response to the same treatment, suffered a relapse two months later when other leukemia cells appeared that did not harbor the specific cell receptor targeted by the therapy.

"This study describes how these cells have a potent anticancer effect in children," said co-first author Stephan A. Grupp, M.D., Ph.D., of The Children's Hospital of Philadelphia, where both patients were treated in this clinical trial. "However, we also learned that in some patients with ALL, we will need to further modify the treatment to target other molecules on the surface of leukemia cells."

Grupp is the director of Translational Research for the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia, and a professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Michael Kalos, Ph.D., an adjunct associate professor in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine at Pen
'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-426-6063
Children's Hospital of Philadelphia

Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
Perelman School of Medicine, University of Pennsylvania


Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Infusion of stem cells and specially generated T-cells from same donor improves leukemia survival
2. Denosumab reduces burden of giant-cell tumor of the bone
3. Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas
4. UCLA, Caltech research on immune-cell therapy could strengthen promising melanoma treatment
5. Physical therapy as effective as surgery for torn meniscus and arthritis of the knee
6. PREFERRED Therapy Providers Selects WebOutcomes to Deliver Web-Based Outcomes for Their National Provider Network
7. Gene Therapy for Human Disease: Clinical Advances and Challenges
8. Immune Therapy Shows Early Promise for Advanced Leukemia
9. Dennis R. Hill MD Announces Launch of High Dose Rate Brachytherapy of Prostate Cancer Website
10. Therapy as Good as Surgery for Some With Torn Knee Cartilage
11. Women's Excellence in Pelvic Floor Physical Therapy Near Pontiac, MI, Now Offers Therapy After Vaginal Delivery to Prevent Urinary Incontinence, Improve Sexual Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA Today ... years, according to the American Dental Association. According to a study by the American ... 1.1 million in a single year to 2.2 million a year. Dentists and ADA ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Constantin Vasilica, 48 ... by tissue injury caused by diabetes after many years of suffering and using medications ... and he didn’t want to ask for extra time off or wait longer hours ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... (EMSI), a leading provider of medical information, risk management and investigative services, ... evolution and direction toward focused, expert information solutions that improve business outcomes ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American Medical ... least once in their lives. Often time, low back and sciatic pain can happen ... only be managed clinically with powerful pain medication or spinal surgery. Dynamic Health ...
Breaking Medicine News(10 mins):Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2
... Sept. 10 Birner Dental Management Services, Inc. (Nasdaq: ... dental practices announced its regular quarterly dividend. The Company,s ... cents per share of common stock. The dividend is payable ... , Birner Dental Management Services, Inc. acquires, develops, ...
... , MENLO PARK, Calif., Sept. 10 ... today announced that new research on nicotine dependence is featured ... and Endophenotypes: Foundations for Genetic Studies of Nicotine Use ... Center for Health Sciences, was the senior scientific editor of ...
... , QUINCY, Mass., Sept. 10 ... flu shots as part of its Health & Wellness initiative in ... during the cough and cold season . This year, Stop & ... Stop & Shop card holders in the pharmacy department beginning Friday, ...
... rare and dangerous disease, new laboratory research at The University ... lead researchers toward clues in more common diseases, including highly ... in the Sept. 11 issue of the journal Molecular ... damage sites is controlled by replication in both FA and ...
... 10, 2009 When a terrorist bomb explodes, a ... region, or wildfires ravage homes and businesses, plastic surgeons ... But they should be, UT Southwestern Medical ... September issue of Plastic and Reconstructive Surgery . ...
... RESTON, Va.SNM applauds the U.S. Food and Drug Administration,s ... Zevalin, as a front-line treatment of non-Hodgkin,s lymphoma ... with non-Hodgkin,s lymphoma," said Michael M. Graham, M.D., Ph.D., ... the University of Iowa Carver College of Medicine. "We,ve ...
Cached Medicine News:Health News:SRI International's Research on Nicotine Use and Dependence Featured in the National Cancer Institute's Tobacco Control Monograph Series 2Health News:SRI International's Research on Nicotine Use and Dependence Featured in the National Cancer Institute's Tobacco Control Monograph Series 3Health News:Stop & Shop To Offer Seasonal Flu Shots 2Health News:Stop & Shop To Offer Seasonal Flu Shots 3Health News:Replication at DNA damage sites highlights Fanconi anemia and breast cancer proteins 2Health News:Plastic surgeons should be part of disaster relief planning, response 2Health News:Plastic surgeons should be part of disaster relief planning, response 3Health News:SNM applauds FDA's decision to approve Zevalin 2
(Date:8/3/2015)... 2015  Encision Inc. (PK:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 30, 2015. The Company posted quarterly net ... of $213 thousand, or $(0.02) per share. These results ... net loss of $202 thousand, or $(0.02) per share, ...
(Date:8/2/2015)... LONDON , August 3, 2015 ... Dechra Pharmaceuticals PLC ("Dechra" or the "Company") ... share purchase agreement ("SPA") with Mr. Marijan Han ... voting rights) in Genera d.d. ("Genera"), a Croatian listed ... (HRK179.60) per share, which is equivalent to €51.4 million ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Immunomedics, Inc. (Nasdaq: IMMU ) , ... to treat cancer and other serious diseases, today ... Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, ... animal models as an effective new therapy. ...
... Fla., Jan. 19 A new approach to unblocking ... down time, lower costs and less risk overall, particularly ... the 21st annual International Symposium on Endovascular Therapy (ISET). ... over bypass surgery to open their blocked arteries. New ...
Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
... Ultralight Jarrod Goggles have set the ... Nonslip soft silicone saddle nose bridge. ... better and lasts longer. Adjustable elastic ... without breakable plastic strap clips. 0.75 ...
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Portable shields for your safety and convenience....
Medicine Products: